|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Japan Pharma Outlook 2015: 2015 –Year to Watch Out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strategies to ... Onconova Therapeutics Inc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... . The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and ... Therapeutic Class Overview: Treating Refractory Hematological Malignancies Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs ... Japan Pharma Outlook 2016: JP Giants leaning in for becoming a Speciality Global Pharma JP Giants leaning in for becoming a Speciality Global Pharma Sakigake designation – A Push from government to “Innovate”! “Essential drugs” exemption from Z2 rule- Balancing long listed pricing pressure! Authorized Generics, Biosimilars, and Patent ... Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H1 2018 Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H1 2018 SUMMARY Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or ... SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019 SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019 SUMMARY Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules. Out of which ... Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – ... Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018 Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018 SUMMARY According to the recently published report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 ... Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors ... ) - Significant Upside still Remains: Bendamustine + Rigosertib + Cash to In-license More! PI3K inhibitors - Pipeline Insight, 2022 ... Regulatory and Sales Milestones for Rigosertib in Greater China. In December 2019, Onconova ... into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program ... Research programme: anti-cancer therapeutics Rigosertib Seletalisib Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: PLK Targeted Therapies In Clinical Trials: > 10 ... Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvement in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative therapies for ... Epidermolysis bullosa - Pipeline Insight, 2021 ... QR-313 beremagene geperpavec AC-203 BPM31510 Rigosertib Sodium INM-755 USB-002 ... Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022 ... Products Volasertib CYC-140 Onvansertib Rigosertib SOL686 Serine/Threonine Protein Kinase PLK1 - Pipeline Review, H1 2020 Serine/Threonine Protein Kinase PLK1 - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H1 2020'; Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/ ... Chronic myelomonocytic leukaemia - Pipeline Insight, 2021 ... APR-246 CFI-400945 PRT543 Rigosertib Histamine dihydrochloride injection Arsenic trioxide ... KRAS Market by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031 The NRAS, HRAS and KRAS market is expected to reach USD 73 million in 2021 and anticipated to grow at a CAGR of 53.6% during the forecast period 2021-2031 In 2020, an estimated 10 million reported fatalities were attributed to cancer, standing as a ... SYMBIO - Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More! ... product portfolio- Label expansion of TREAKISYM, Rigosertib IV and Rigosertib Oral and cash for ... titled “Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!” SymBio pharma - TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More! ... (4582) licensed Onconova’s Rigosertib (SyB L-1101, PhI, RRMDS ... of the upcoming PhIII data in US of Rigosertib IV (Rig. IV) in RRMDS by YE13. Disappointing ... 2013, titled, "TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to ... Onconova Therapeutics (ONTX) -Near-Term Catalysts = Upside Still! ... that ONTX's lead drug, Estybon (Rigosertib/ ON 01910.Na, PhIII, PI3K-PLK inhibitor ... |